Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.

BACKGROUND AND OBJECTIVES Second cancer has been associated with non-Hodgkin's Lymphoma (NHL) treatment, but few studies have addressed this issue considering specific treatments. DESIGN AND METHODS We estimated risk by standardized incidence ratios (SIR) and absolute excess risk (AER) based on general population rates (European Network of Cancer Registries) in 748 patients (aged 15-82 years) treated for aggressive NHL in four successive EORTC (European Organization for Research on Treatment of Cancer) trials. RESULTS All patients received fully-dosed CHOP-like chemotherapy, 65% received involved-field radiotherapy and 14% high-dose treatment. Half of the patients needed salvage treatment and 37% were followed for more than 10 years. The cause of death was NHL in 79% of the patients; 4% died of second cancer (median survival 8.9 (0.8- 20.5) years). Cumulative incidences (death from any cause being a competing event) were 5% and 11% for solid cancer and 1% and 3% for acute myeloid leukemia/myelodysplastic syndrome at 10 and 15 years, respectively. Cancer risk appeared age-related: in young patients high risks were observed for leukemia (SIR 16.7,95% CI 1.4-93.1,AER 5.0), Hodgkin's lymphoma (SIR 60.1,95% CI 12.4-175.2, AER 15.7), colorectal cancer (SIR 12.5, 95% CI 2.6-36.5, AER 14.7) and lung cancer (SIR 15.4; 95% CI 4.2-39.4, AER 19.8), while risk in patients older than 45 years matched than that in the normal population. The risk of cancer was significantly raised by smoking and salvage treatment. INTERPRETATION AND CONCLUSIONS Half of the patients die of aggressive NHL before living long enough to experience second cancer. Only young patients have a high risk of second cancer during follow-up beyond 10 years.

[1]  R. Clough,et al.  Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Stovall,et al.  Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. , 2005, Blood.

[3]  M. Gail,et al.  Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. , 2005, Journal of the National Cancer Institute.

[4]  J. Raemaekers,et al.  Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. , 2005, Clinical lymphoma & myeloma.

[5]  B. Hancock,et al.  Second primary malignancies after treatment for malignant lymphoma , 2005, British Journal of Cancer.

[6]  J. Friedberg,et al.  Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  I. Toma-Dasu,et al.  The use of risk estimation models for the induction of secondary cancers following radiotherapy , 2005, Acta oncologica.

[8]  J. Baars,et al.  Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials. , 2004, European journal of cancer.

[9]  H. V. Gelder.  The Netherlands , 2004, Constitutions of Europe (2 vols.).

[10]  L. Robison,et al.  High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Gaulard,et al.  Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. , 2003, Blood.

[12]  A. Broeks,et al.  Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. , 2003, Journal of the National Cancer Institute.

[13]  E. Hall,et al.  Radiation-induced second cancers: the impact of 3D-CRT and IMRT. , 2003, International journal of radiation oncology, biology, physics.

[14]  M. Stovall,et al.  Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  John D Boice,et al.  Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. , 2002, Journal of the National Cancer Institute.

[16]  K. Hemminki,et al.  Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a search for common mechanisms , 2001, British Journal of Cancer.

[17]  H. Kluin-Nelemans,et al.  Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. , 2001, Journal of the National Cancer Institute.

[18]  P. Brennan,et al.  Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia , 2000, British Journal of Cancer.

[19]  T. Lister,et al.  Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Marcus,et al.  The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. , 1999, International journal of radiation oncology, biology, physics.

[21]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[22]  M. Domanski,et al.  Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Hancock,et al.  Long-Term Complications of Treatment and Causes of Mortality After Hodgkin's Disease. , 1996, Seminars in radiation oncology.

[24]  L. Robison,et al.  Breast cancer and other second neoplasms after childhood Hodgkin's disease. , 1996, The New England journal of medicine.

[25]  A. Hagenbeek,et al.  Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. , 1995, Journal of the National Cancer Institute.

[26]  S. Hancock,et al.  Thyroid abnormalities after therapeutic external radiation. , 1995, International journal of radiation oncology, biology, physics.

[27]  A. Hagenbeek,et al.  Risk of leukemia following treatment for non-Hodgkin's lymphoma. , 1994, Journal of the National Cancer Institute.

[28]  P. Silcocks,et al.  Estimating confidence limits on a standardised mortality ratio when the expected number is not error free. , 1994, Journal of epidemiology and community health.

[29]  S. Wacholder,et al.  Second cancers among long-term survivors of non-Hodgkin's lymphoma. , 1993, Journal of the National Cancer Institute.

[30]  M. Lishner,et al.  Second malignancies following treatment in non-Hodgkin's lymphoma. , 1993, Leukemia & lymphoma.

[31]  N. Janjan,et al.  Dosimetry of the breast for determining carcinogenic risk in mantle irradiation. , 1991, International journal of radiation oncology, biology, physics.

[32]  M. van Glabbeke,et al.  Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  F. Liddell,et al.  Simple exact analysis of the standardised mortality ratio. , 1984, Journal of epidemiology and community health.

[34]  H. Kaplan,et al.  Clinical trials in the non-Hodgkin's lymphomata at Stanford University experimental design and preliminary results. , 1975, The British journal of cancer. Supplement.

[35]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[36]  A. Swerdlow,et al.  Late effects after treatment for Hodgkin lymphoma. , 2004 .

[37]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[38]  B. Meunier,et al.  [Breast cancer after treatment of Hodgkin's disease]. , 1995, Journal de gynecologie, obstetrique et biologie de la reproduction.

[39]  C. de Wolf‐Peeters,et al.  EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[41]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.

[42]  R. Somers,et al.  Report on the EORTC lymphoma trial 20751. , 1983, International journal of radiation oncology, biology, physics.

[43]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[44]  D.,et al.  Regression Models and Life-Tables , 2022 .